Literature DB >> 19036815

Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion.

Timothy R Wagenaar1, Bernard Moss.   

Abstract

Many animal viruses induce cells to fuse and form syncytia. For vaccinia virus, this phenomenon is associated with mutations affecting the A56 and K2 proteins, which form a multimer (A56/K2) on the surface of infected cells. Recent evidence that A56/K2 interacts with the entry/fusion complex (EFC) and that the EFC is necessary for syncytium formation furnishes a strong connection between virus entry and cell fusion. Among the important remaining questions are whether A56/K2 can prevent virus entry as well as cell-cell fusion and whether these two viral proteins are sufficient as well as necessary for this. To answer these questions, we transiently and stably expressed A56 and K2 in uninfected cells. Uninfected cells expressing A56 and K2 exhibited resistance to fusing with A56 mutant virus-infected cells, whereas expression of A56 or K2 alone induced little or no resistance, which fits with the need for both proteins to bind the EFC. Furthermore, transient or stable expression of A56/K2 interfered with virus entry and replication as determined by inhibition of early expression of a luciferase reporter gene, virus production, and plaque formation. The specificity of this effect was demonstrated by restoring entry after enzymatically removing a chimeric glycophosphatidylinositol-anchored A56/K2 or by binding a monoclonal antibody to A56. Importantly, the antibody disrupted the interaction between A56/K2 and the EFC without disrupting the A56-K2 interaction itself. Thus, we have shown that A56/K2 is sufficient to prevent virus entry and fusion as well as formation of syncytia through interaction with the EFC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036815      PMCID: PMC2643798          DOI: 10.1128/JVI.01684-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein.

Authors:  Patricia L Earl; Jeffrey L Americo; Bernard Moss
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

2.  The mode of entry of vaccinia virus into L cells.

Authors:  J A Armstrong; D H Metz; M R Young
Journal:  J Gen Virol       Date:  1973-12       Impact factor: 3.891

3.  Biogenesis of poxviruses: interrelationship between hemagglutinin production and polykaryocytosis.

Authors:  Y Ichihashi; S Dales
Journal:  Virology       Date:  1971-12       Impact factor: 3.616

4.  Further investigations on the mode of entry of vaccinia virus into cells.

Authors:  A Chang; D H Metz
Journal:  J Gen Virol       Date:  1976-08       Impact factor: 3.891

5.  Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression.

Authors:  C Flexner; A Hügin; B Moss
Journal:  Nature       Date:  1987 Nov 19-25       Impact factor: 49.962

6.  Plasma membrane localization and fusion inhibitory activity of the cowpox virus serpin SPI-3 require a functional signal sequence and the virus encoded hemagglutinin.

Authors:  Lauren M Brum; Peter C Turner; Heather Devick; M Teresa Baquero; Richard W Moyer
Journal:  Virology       Date:  2003-02-15       Impact factor: 3.616

7.  Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene.

Authors:  H Shida; Y Hinuma; M Hatanaka; M Morita; M Kidokoro; K Suzuki; T Maruyama; F Takahashi-Nishimaki; M Sugimoto; R Kitamura
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

8.  Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene.

Authors:  Tatiana G Senkevich; Brian M Ward; Bernard Moss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment.

Authors:  G Hiller; K Weber
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

10.  Superinfection exclusion of vaccinia virus in virus-infected cell cultures.

Authors:  L Christen; J Seto; E G Niles
Journal:  Virology       Date:  1990-01       Impact factor: 3.616

View more
  21 in total

1.  Vaccinia mature virus fusion regulator A26 protein binds to A16 and G9 proteins of the viral entry fusion complex and dissociates from mature virions at low pH.

Authors:  Shu-Jung Chang; Ao-Chun Shih; Yin-Liang Tang; Wen Chang
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  ORF4 of the Temperate Archaeal Virus SNJ1 Governs the Lysis-Lysogeny Switch and Superinfection Immunity.

Authors:  Beibei Chen; Zhao Chen; Yuchen Wang; Han Gong; Linshan Sima; Jiao Wang; Shushan Ouyang; Wenqiang Gan; Mart Krupovic; Xiangdong Chen; Shishen Du
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

Review 3.  Poxvirus proteomics and virus-host protein interactions.

Authors:  Kim Van Vliet; Mohamed R Mohamed; Leiliang Zhang; Nancy Yaneth Villa; Steven J Werden; Jia Liu; Grant McFadden
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

Review 4.  The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.

Authors:  Brian C DeHaven; Kushol Gupta; Stuart N Isaacs
Journal:  J Gen Virol       Date:  2011-06-29       Impact factor: 3.891

5.  The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein.

Authors:  Kaori Shinoda; Linda S Wyatt; Bernard Moss
Journal:  Virology       Date:  2010-06-17       Impact factor: 3.616

6.  A novel mode of poxvirus superinfection exclusion that prevents fusion of the lipid bilayers of viral and cellular membranes.

Authors:  Jason P Laliberte; Bernard Moss
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

Review 7.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

8.  Triad of human cellular proteins, IRF2, FAM111A, and RFC3, restrict replication of orthopoxvirus SPI-1 host-range mutants.

Authors:  Debasis Panda; Daniel J Fernandez; Madhu Lal; Eugen Buehler; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-20       Impact factor: 11.205

9.  Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses.

Authors:  P S Satheshkumar; Bernard Moss
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

10.  Induction of cell-cell fusion by ectromelia virus is not inhibited by its fusion inhibitory complex.

Authors:  Noam Erez; Nir Paran; Galia Maik-Rachline; Boaz Politi; Tomer Israely; Paula Schnider; Pinhas Fuchs; Sharon Melamed; Shlomo Lustig
Journal:  Virol J       Date:  2009-09-29       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.